DOCSLIB.ORG

3 a Reappraisal of the Role of Alginate in GERD Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3 a Reappraisal of the Role of Alginate in GERD Management A Reappraisal of the Role of Alginate in GERD Management Edoardo V. Savarino MD, PhD Associate Professor of Gastroenterology University of Padova Italy Global Prevalence of GERD N=108 studies included in the meta-analysis Prevalence varied according to country (from 2.5% in China to 51.2% in Greece) In case of weekly heartburn/regurgitation was considered, pooled prevalence was 13.3% Risk factors: ≥50 years, smoking, NSAID/aspirin use and obesity Eusebi LH, et al. Gut 2018; 67:430–440 AllAll--Cause/CancerCause/Cancer--SpecificSpecific Mortality in GERD The HUNT study, a Norwegian population-based cohort study, was used to identify individuals with and without reflux in 1995– 997 and 2006–2008, with follow-up until 2014 All-cause mortality and cancer-specific mortality were assessed from the Norwegian Cause of Death Registry and Cancer Registry Ness-Jensen E, et al. Gut 2016;0:1–7. doi:10.1136/gutjnl-2016-312514 Clinical Manifestations of GERD Likely • Heartburn/Burning discomfort Due to Reflux • Regurgitation • Chest Pain (rule out heart disease!) • Dysphagia • Dental erosions • ENT/Cough/Asthma • Sleep disturbances • Dyspeptic symptoms: • EPS (epigastric pain and/or burning), • PDS (Bloating, Belching, Nausea, Vomiting, Early satiety, post-prandial fullness) Locke GR 3 rd et al. Gastroenterology 1997; 112(5):1448-56 Talley N. Aliment Pharmacol Ther 2004; 20 Suppl 5:27-37 Bardhan KD et al. Digestion 2004; 69(4):229-37 GERD: Therapy Proton pump inhibitors (PPIs) represent the mainstay of all acid-related diseases AGA Medical Position Statement on the Management of GERD. Gastroenterology 2008;135:1383–1391 Epidemiology of PPI Efficacy Boeckxstaens G, et al. Gut. 2014;63(7):1185-93. Partial Symptom--ResponseResponse to PPI in Patients with NERD or ERD • Post-hoc analysis of 4 RCTs (db, mc) – NERD (n=2,645) Armstrong et al, APT 2004 – Esophagitis (n=3,251) Labenz et al, APT 2005 NERD Esophagitis Symptoms ≥2 days 26.2% 19.3% Symptoms ≥3 days 19.9% 14.0% Partial symptom-response: ≥3 days with heartburn after 4 weeks and reduced heartburn frequency compared to baseline Bytzer P et al, Aliment Pharmacol Ther. 2012; 36(7):635-43 Impedance--pHpH Stratification of Patients with Typical Reflux Symptoms PUTATIVE MECHANISMS FOR PARTIAL /L ACK OF RESPONSE TO PPI T HERAPY : Poor Compliance and improper timing of PPI PPI administration Reduced PPI bioavailability, rapid metabolism PPI Residual acid reflux, NAB Eosinophilic esophagitis Weakly acidic reflux Duodeno-gastroesophageal/bile reflux Visceral hypersensitivity Delayed gastric emptying Psychological comorbidity PPI Functional Heartburn Concomitant functional gastric and/or bowel disorders PPI Savarino E, et al. Nat Rev Gastroenterol Hepatol. 2013;10(6):371-80 Moayyedi P and Talley NJ. Lancet 2006; 367:2086-100 Reported Adverse Events of PPIs Reimer C. et al. Best Pract Res Clin Gastroenterol 2013; 27:443–454 Savarino E, et al. Dig Liver Dis. 2016;48(8):851-9 Complications of PPI Therapy APPLICATION OF THE HILL CRITERIA TO SOME OF THE PROPOSED ASSOCIATIONS WITH LONG -TERM PPI T HERAPY Vaezi MF, et al .Gastroenterology 2017;153:35–48 Additional Treatments: What’s Now on the Shelf Lifestyle Modifications Proton Pump Inhibitors TLESR Reducers Promotility Drugs Alginates Sucralfate Visceral Pain Modulators Surgery Alternative Medicine (Hypnotherapy) Psychological Treatment Functional Gastrointestinal Disorders Treatment Origin of Alginate Alginates are products made ofof alginic acid, aachemicalchemical compound ofof natural origin that isis obtained from various algae ofof the genus Laminaria that grow inin the coastal areas ofof the Atlantic OceanOcean.. Laminaria hyperborea Demonstration of the Barrier Effect of Alginate in vitro Alginates Are Products Made by Alginic Acid→ Gel Barrier The addition of bicarbonate, interacting with the acid gastric juice, generates carbon dioxide which makes the gel floating → sort of "raft" viscose that floats on top of the gastric content by creating an obstacle to the gastro-oesophageal acid, food, pepsin and bile reflux Scarpignato C et al. Therapy Perspect 2011;16:1-37 Demonstration of the Barrier Effect of Alginate in vivo Zentilin P, et al. Aliment Pharmacol Ther 2005;21:29-34 Savarino E, et al. World J Gastroenterol. 2012;18(32):4371-8 Rohof WO et al, Clin Gastroenterol Hepatol. 2013 Dec;11(12):1585-91 Higher Efficacy of Sodium Alginate/Potassium Bicarbonate in Controlling Reflux Burden Rohof et al., Clin Gastroenterol Hepatol 2013 ;11: 1585-1591 An Evaluation of the Antireflux Properties of Sodium Alginate by Means of MIIMII--pHpH p<0,05 18,0 16,0 14,0 12,0 10,0 Basal After alginate intake 8,0 6,0 %%atat time time pHpH << (median(median 4 4 values) values) 4,0 p<0,05 p<0,05 2,0 0,0 Right lateral Supine Zentilin P et al, Aliment Pharmacol Ther. 2005;21(1):29-42005 An Alginate--AntacidAntacid Formulation Localizes to the Acid Pocket to Reduce AAcidcid Reflux Scintigraphic image of acid pocket (A) and 111mIn-labeled alginate-antacid (B) and the two recordings superimposed ©. It is demonstrated that the labeled alginate-antacid is present on top and co-localizes with the acid pocket in the proximal stomach. Rohof WO et al. Clin Gastroenterol Hepatol. 2013;11(12):1585-91 Superficial Esophageal Mucosal Afferent Nerves and Reflux Hypersensitivity in NERD A prospective study of 10 HVs. 13 NERD, 11 ERD, and 16 BE with proximal/distal biopsies Nerve fibers were searched with a labeled antibody against calcitonin gene-related peptide (CGRP), a marker of nociceptive sensory nerves. CGRP (green) and PGP (purple) co- localizing nerve fibers within the esophageal mucosal epithelium. The top panels demonstrate a superficial fiber in a patient with NERD. The lower panels demonstrate a deep fiber typical of BE, ERD, or HV. Woodland P, et al. Gastroenterology 2017;153:1230–1239 Savarino E, et al. Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):634-636 Topical Protection of Human Esophageal Mucosal Integrity Three distal esophageal biopsies from 22 patients with heartburn, and 22 control subjects. In mini-Ussing chambers, the change in TER of biopsies when exposed to neutral, weakly acidic, and acidic solutions The experiment was repeated in 10 patients after pretreatment of biopsies with sodium alginate, viscous control, or liquid control “protectant” solutions A fter Without pretreatment of biopsies pretreatment of biopsies Woodland P, et al. Am J Gastroenterol. 2013 Apr;108(4):535-43 Topical Protection of Human Esophageal Mucosal Integrity In vitro topical application of an alginate solution can protect mucosal biopsies against acid- induced changes in transepithelial electrical resistance (TER) Distal esophageal mucosal biopsies were (N=12) studied in Ussing chambers. Aim: to assess prolonged protection in a biopsy model In biopsies, 60 min after protection with alginate solution, the acidic exposure caused a 8.3 2.2% change in TER compared with 25.1 4.5% change after protection with the viscous control ( P 0.05). Labeled alginate could be seen coating the luminal surface in all cases. In vitro, alginate solutions can adhere to the esophageal mucosa for up to 1 h and exert a topical protectant effect. Woodland P, et al. Am J Physiol Gastrointest Liver Physiol. 2015;308(12):G975-80 Efficacy of Sodium AAlginatelginate Alone in Patients with GERD ––AARCT in Referral Centers Pouchain D et al., BMC Gastroenterol. 2012 Feb 23;12:18 Efficacy of Sodium AAlginatelginate Alone in Patients with NERD ––AARCT in Referral Centers Chiu et al., Aliment Pharmacol Ther 2013; 38: 1054-1064 Efficacy of Adding SSodiumodium AAlginatelginate to Omeprazole in Patients with NERD ––AARCT Omeprazole 20 od + Omeprazole 20 od + Na alginate/Na bicarbonate 30 ml qid Placebo 30 ml qid Manabe N et al., Diseases of the Esophagus 2012; 25:373–380 Efficacy of Adding SSodiumodium AAlginatelginate to Omeprazole in Patients with Regurgitation Coyle C et al, Aliment Pharmacol Ther. 2017 Jun;45(12):1524-1533 Relief of Dyspepsia Symptoms by An Acid PocketPocket--targetingtargeting Alginate--AntacidAntacid A double-blind, placebo-controlled, pilot study in GERD N= 110 with GERD received Gaviscon DA or placebo tablets for 7 consecutive days Thomas E et al., Aliment Pharmacol Ther. 2014;39(6):595-602 Effectiveness of Sodium Alginate + Sodium Bicarbonate in Controlling Symptoms of GERD in Pregnancy Coutesy of Carmelo Scarpignato The Role of An Alginate Suspension on Pepsin and Bile Acids Coutesy of Carmelo Scarpignato Strugala et al, J Pharma Pharmacol 2009; 61:1021-1028 The Value of a Liquid Alginate Suspension in the Management of laryngopharyngeal Reflux Reflux Symptom Index (RSI) Reflux Finding Score (RFS) 30 15 Base Base 25 20 10 15 * * 10 5 5 0 0 GavisconSodio Controlloplacebo GavisconSodio placeboControllo alginato/potassi alginato/potassi *P=00.008 vsbicarbonato controllo ** P=0.005 vs controllo bicarbonato McGlashan JA et al. Eur Arch Otorhinolaryngol. 2009 Feb;266(2):243-51 Alginate Therapy is Effective in GERD N=14 studies included in the meta-analysis (N=2095 subjects) Alginate-based therapies increased the odds of resolution of GERD symptoms when compared to placebo or antacids (OR: 4.42; 95% CI 2.45–7.97) , whereas they did not compare to PPIs or H2RAs (OR: 0.58; 95% CI 0.27–1.22). Leiman DA, et al. Dis Esophagus 2017;30(5):1-9 Are the Alginate--containingcontaining Formulations All Equal? Coutesy of Carmelo Scarpignato Another Useful and Interesting Indication…….. Deprescribing Proton Pump Inhibitors Alginate! OLDER ADULTS SHOULD BE PERIODICALLY EVALUATED FOR THE NEED
Load more

Recommended publications
  • The Comparison of the Effect Between Alginate-Based Raft-Forming Liquid and Alginate Liquid on Gastroesophageal Reflux Disease and Gastric Ulcer in Rats
    Online - 2455-3891 Vol 10, Issue 12, 2017 Print - 0974-2441 Research Article THE COMPARISON OF THE EFFECT BETWEEN ALGINATE-BASED RAFT-FORMING LIQUID AND ALGINATE LIQUID ON GASTROESOPHAGEAL REFLUX DISEASE AND GASTRIC ULCER IN RATS HAKIM BANGUN1*, ANAYANTI ARIANTO1, RIRIN ASTYA1, GONTAR A SIREGAR2 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Nanomedicine Center, University of Sumatera Utara, Jl. Tri Dharma No. 5, Kampus USU, Medan, Indonesia. 2Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Jl Dr. T. Mansyur No. 5, Kampus USU, Medan, Indonesia. Email: [email protected] Received: 04 July 2017, Revised and Accepted: 16 August 2017 ABSTRACT Objective: The objective of the study was to compare the effect between alginate (Alg)-based raft-forming and Alg liquid on healing gastroesophageal reflux disease (GERD) and gastric ulcer in rats. Methods: Each of the 18 fasted rats was given 1 ml acidified pepsin. Then, rats were divided into three groups. Each group consisted of six rats. Group 1 (negative control) was orally given 1 ml distilled water, Group 2 was given 1 ml Alg-based raft-forming liquid, and Group 3 was given 1 ml Alg liquid. Then, the abdomen of rats was incised under anesthesia with ketamine, and then both their pylorus and the forestomach were ligated to form gastric reflux. After 4 hrs, all rats were killed with chloroform and their esophagus and stomach were examined macroscopically and microscopically (histopathology). Results: On macroscopic observation, all of the Group 1 rats (negative control) showed esophageal lesions and gastric lesions. Four rats of Group 2 (given Alg-based raft-forming) showed no esophageal lesion and two more rats showed a slight lesion, but all of the tested rats showed gastric lesions.
    [Show full text]
  • RAFT FORMING SYSTEM a REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Journal of Drug Delivery and Therapeutics (JDDT) Bhavsar et al Journal of Drug Delivery & Therapeutics; 2012, 2(5), 123-128 123 Available online at http://jddtonline.info REVIEW ARTICLE ADVANCES IN GRDDS: RAFT FORMING SYSTEM A REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C. Sini Surendran, Shah Viral H, Upadhyay UM Dept. of pharmaceutics, Sigma Institute of Pharmacy, Bakrol, Vadodara(Gujarat), India *Corresponding Author’s Ph: +91-9725512814, Email id: [email protected] Received 06 June 2012; Review Completed 26 Aug 2012; Accepted 26 Aug 2012, Available online 15 Sep 2012 ABSTRACT: In recent years several advancements has been made in research and development of Gastro retentive drug delivery system to overcome the drawback of non-site specificity when drug administered orally. In order to understand various physiological difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention time. We have reviewed various gastro retentive approaches designed and developed until now i.e. floating drug dosage systems (FDDS), swelling or expanding systems, mucoadhesive systems, high density system, Raft forming system, magnetic systems. Among these systems, the review summarizes the special focus on raft forming approach which comes under floating drug delivery system. Raft system incorporates alginate gels which have carbonate components react with gastric acid causes bubbles and this enables floating. Finally, Evaluation, advantages, disadvantages, future potential and marketed preparation of raft forming approach in gastro retentive drug delivery systems were covered. Key words-Advances in GRDDS, Raft forming system, alginic acid, gaviscon, INTRODUCTION: Conventional oral delivery is widely used in 4) Drugs with a narrow window of absorption E.g.
    [Show full text]
  • Gastroesophageal Reflux Disease (GERD)
    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • The Role of Alginate-Based Therapy in Gastroesophageal Reflux Disease
    Romanian Journal of MEDICAL PRACTICE General articles Ref: Ro J Med Pract. 2020;15(3) DOI: 10.37897/RJMP.2020.3.5 The role of alginate-based therapy in gastroesophageal reflux disease Assoc. Prof. Ana-Maria SINGEAP1,2, MD, PhD, Assist. Prof. Laura HUIBAN1,2, MD, PhD student, Assist. Prof. Stefan CHIRIAC1,2, MD, PhD, Assist. Prof. Tudor CUCIUREANU1,2, MD, PhD student, Prof. Anca TRIFAN1,2, MD, PhD, FRCP 1 “Gr.T. Popa” University of Medicine and Pharmacy, Iasi, Romania 2 Institute of Gastroenterology and Hepatology, “St. Spiridon” Emergency Hospital, Iasi, Romania Abstract Gastroesophageal reflux disease (GERD) is one of the most common digestive pathologies, with worldwide spread and increasing incidence. Due to the chronic nature of this condition, the dreaded complications that can occur during evolution and the negative impact on patients' quality of life, it is imperative to administer symptomatic treatment to eliminate or improve symptoms, cure erosive esophagitis and prevent recurrences and complications. Alginic acid formulations have a unique, particular mechanism of action, acting as a long-lasting physical barrier floating on the surface of the gastric pool, displacing the postprandial gastric acid pocket and protecting esophagus mucosa during reflux episodes. Numerous studies evaluated the efficacy of alginate treatment in GERD, by comparison to antacids, proton pump inhibitors (PPIs), histamine 2 receptor antagonists (H2RAs), or placebo. While most studies found superiority of alginate treatment when compared to antacids or to placebo, PPIs treatment was overall more effective than alginate in controlling GERD symptoms. There were some trials that reported alginate non-inferiority when compared to PPIs, especially in the setting of NERD.
    [Show full text]
  • ACID-PEPTIC DISEASE Methodology: Expert Opinion Issue Date: 4-97 Champion: GI Dept
    KAISER PERMANENTE OHIO ACID-PEPTIC DISEASE Methodology: Expert Opinion Issue Date: 4-97 Champion: GI Dept. Most Recent Update: 4-10, 4-12 Key Stakeholders: GI, IM Depts. Next Update: 4-14 The following guidelines have been developed to assist Primary Care physicians and other health care professionals in the management of uncomplicated dyspepsia, nonsteroidal anti-inflammatory drug (NSAID)-induced dyspepsia, and gastroesophageal reflux disease (GERD). It does not address the man- agement of irritable bowel syndrome, pancreatic disease, biliary tract disease, or other serious gastrointestinal disorders Initial Evaluation Pharmacotherapy A clinical evaluation is recommended to identify the etiol- UNINVESTIGATED DYSPEPSIA (see Figure 1) ogy of dyspeptic symptoms and determine appropriate (with or without history of ulcer) management. Initiation of treatment with high-dose H2-receptor Referral to endoscopy is recommended for patients pre- antagonists at time of H. pylori testing is recom- senting with “alarm symptoms” suggestive of a serious mended. gastrointestinal disorder. If H. pylori test results are positive, then treatment with antibiotics and a proton pump inhibitor is rec- Helicobacter pylori (H. pylori) serum antibody testing ommended. is recommended for patients with uncomplicated and NSAID-induced dyspepsia not associated with GERD If H. pylori test results are negative and symptoms or alarm symptoms. persist, then treatment with a proton pump inhibi- tor is recommended. Test patients for H. pylori only after ruling out a diagnosis of GERD, biliary symptoms, or alarm symptoms suggestive of an TREATMENT OF H. PYLORI underlying serious gastrointestinal disease (e.g., gastric can- cer, pancreatitis, etc.). The following 3-drug regimen is first-line therapy for eradication of H.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Alginate Forming In-Situ Gel for Treating Peptic Ulcers and Reflux Disorders
    JPSBR: Volume 5, Issue 2: 2015 (172-179) ISSN NO. 2271-3681 A Review On: Alginate Forming In-Situ Gel for Treating Peptic Ulcers and Reflux Disorders I.S Sengupta*1, SH Shah2, N. Shah2 1. Student of Department of Pharmaceutical technology, M.Pharm 4th semester, L.J institute of pharmacy, Ahmedabad, Gujarat, India 2. HOD of Department of Pharmaceutical technology, L.J institute of pharmacy, Ahmedabad, Gujarat 3. Assistant professor of Department of Pharmaceutical technology, L.J institute of pharmacy, Ahmedabad, Gujarat, India ABSTRACT: The oral delivery of drugs with a narrow absorption window in the gastrointestinal tract (GIT) is often limited by poor bioavailability with conventional dosage forms due to incomplete drug release and short residence time at the site of absorption. In-situ gel provides the best way to overcome problems of immediate release and short gastrointestinal residence of liquids. The in situ gel dosage form is a liquid before administration and after it comes in contact with gastric contents due to one or more mechanisms gets converted to gel which floats on gastric contents. This achieves increased residence as well as sustained release. This approach is useful for systemic as well as local effect of drugs administered. In the presence of gastric acid, alginates precipitate, forming a gel.Alginate-based raft-forming formulations usually contain sodium or potassium bicarbonate; in thepresence of gastric acid, the bicarbonate is converted to carbon dioxide which becomes entrapped within the gel precipitate, converting it into a foam which floats on the surface of the gastric contents, much like a raft on water.
    [Show full text]
  • Oral Compositions for the Treatment of Gastroesophageal Reflux Disease
    (19) TZZ¥____T (11) EP 3 184 115 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 28.06.2017 Bulletin 2017/26 A61K 36/48 (2006.01) A61P 1/04 (2006.01) (21) Application number: 16205086.8 (22) Date of filing: 19.12.2016 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • MADARO, Elena GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 20090 TREZZANO SUL NAVIGLIO (MI) (IT) PL PT RO RS SE SI SK SM TR • DOMINONI, Mirko Designated Extension States: 20090 TREZZANO SUL NAVIGLIO (MI) (IT) BA ME • MARCELLONI, Luciano Designated Validation States: 20090 TREZZANO SUL NAVIGLIO (MI) (IT) MA MD • COSTA, Andrea 20090 TREZZANO SUL NAVIGLIO (MI) (IT) (30) Priority: 22.12.2015 IT UB20159732 (74) Representative: Bianchetti Bracco Minoja S.r.l. (71) Applicant: S.I.I.T. S.r.l.-Servizio Internazionale Via Plinio, 63 Imballaggi 20129 Milano (IT) Termosaldanti 20090 Trezzano sul Naviglio MI (IT) (54) ORAL COMPOSITIONS FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (57) There is disclosed an oral composition for use - alginic acid or a salt thereof in the treatment of gastroesophageal reflux disease, - carbomer comprising the following ingredients: - carbonate and/or hydrogen carbonate of a physiologi- - tamarind extract cally compatible alkali or alkaline-earth metal. EP 3 184 115 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 184 115 A1 Description [0001] The present invention relates to an oral composition useful for the treatment of gastroesophageal reflux disease.
    [Show full text]
  • Adhesive Oral Bandages and Oral Pharmaceutical Preparations
    Europaisches Patentamt European Patent Office © Publication number: 0 200 508 Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION © Application number: 86303170.4 © int. CIA A61K 9/70 , A61L 15/06 © Date of filing: 25.04.86 © Priority: 27.04.85 JP 91580/85 © Applicant: NITTO ELECTRIC INDUSTRIAL CO., 27.04.85 JP 91581/85 LTD. No. 1-2, Shimohozumi 1-chome Ibaraki-shi © Date of publication of application: Osaka(JP) 10.12.86 Bulletin 86/45 Applicant: SUNSTAR INC. 3-1 Asahi-cho © Designated Contracting States: Takatsuki-shi Osaka(JP) CH DE FR GB LI NL SE @ Inventor: Inoue, Yuichi Nitto Elec. Ind. Co. Ltd. 1-2 Shinohozumi 1-chome Ibaraki-shi Osaka(JP) Inventor: Horiuchi, Tetuo Nitto Elec. Ind. Co. Ltd. 1-2 Shinohozumi - 1-chome Ibaraki-shi Osaka(JP) Inventor: Hasegawa, Kenji c/o Sunstar Inc 3-1 Asahi-cho Takatsuki-shi Osaka(JP) Inventor: Nakashima, Koichi c/o Sunstar inc 3-1 Asahi-cho Takatsuki-shi Osaka(JP) Inventor: Ysuyoshi, Takashi c/o Sunstar inc 3-1 Asahi-cho Takatsuki-shi Osaka(JP) © Representative: Diamond, Bryan Clive Gee & Co. Chancery House Chancery Lane London WC2A 1QU(GB) © Adhesive oral and oral < bandages pharmaceutical preparations. 00 o © A polycarboxylic acid or anhydride, e.g. acrylic The bandage shows strong adhesion for a period IT)or or methacrylic acid polymer or maleic anhydride of at least 3 hours to the oral mucosa or teeth. polymer,polymer, is mixed with a vinyl acetate polymer pref- A topical drug can be incorporated in the adhe- Oerably erably of viscosity-average molecular weight of at sive bandage, to form an oral pharmaceutical prep- CMleast least 60,000, and optionally with a base capable of aration from which the drug is gradually released.
    [Show full text]
  • Free PDF Download
    European Review for Medical and Pharmacological Sciences 2020; 24: 11845-11857 Efficacy and safety of alginate formulations in patients with gastroesophageal reflux disease: a systematic review and meta-analysis of randomized controlled trials C.-X. ZHAO1, J.-W. WANG2, M. GONG3 1Department of Gastroenterology, Zaozhuang Hospital of Traditional Chinese Medicine, Shandong Province, P.R. China 2Zaozhuang Hospital of Traditional Chinese Medicine, Shandong Province, P.R. China 3Department of Pharmacy, Zaozhuang Municipal Hospital, Shandong Province, P.R. China Abstract. – OBJECTIVE: Alginate formula- Key Words: tions are increasingly being used for treating Alginate, Proton pump inhibitors, Gastroesophage- gastroesophageal reflux disease (GERD). How- al reflux disease, Meta-analysis. ever, the benefits of alginate versus control or proton pump inhibitors (PPIs) are somewhat un- clear. We performed a systematic review and Introduction meta-analysis to summarize data from recent randomized controlled trials (RCTs) comparing Gastroesophageal reflux disease (GERD) is a the efficacy and safety of alginate-based for- common gastrointestinal (GI) ailment that affects mulation with PPIs or control for the treatment of GERD. around 18.1%-27.8% of population in North Amer- 1 MATERIALS AND METHODS: PubMed, Em- ica . Classical symptoms of the disease include dis- base, Scopus, BioMed Central, CENTRAL, and tressing heartburn and acid regurgitations, especial- Google scholar databases were searched from ly after meals. Patients may also experience other st th 1 January 2000 to 15 June 2020. Primary symptoms such as epigastric pain, bloating, dyspha- outcome was a reduction of symptoms while gia, laryngitis, and cough2,3. These symptoms have secondary outcomes were adverse events and treatment withdrawals.
    [Show full text]
  • Review Article Current Pharmacological Management of Gastroesophageal Reflux Disease
    Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 983653, 12 pages http://dx.doi.org/10.1155/2013/983653 Review Article Current Pharmacological Management of Gastroesophageal Reflux Disease Yao-Kuang Wang,1 Wen-Hung Hsu,1,2 Sophie S. W. Wang,1,3 Chien-Yu Lu,1,4 Fu-Chen Kuo,5 Yu-Chung Su,4,6 Sheau-Fang Yang,7 Chiao-Yun Chen,3,8 Deng-Chyang Wu,1,2,3,4 and Chao-Hung Kuo1,3,4 1 Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2 Division of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 3 Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 4 Department of Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 5 Department of Health Management, I-Shou University, E-Da Hospital, Kaohsiung, Taiwan 6 Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan 7 Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 8 Department of Medical Imaging, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan Correspondence should be addressed to Chao-Hung Kuo; [email protected] Received 7 May 2013; Accepted 3 June 2013 Academic Editor: Ping-I Hsu Copyright © 2013 Yao-Kuang Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Gastroesophageal reflux disease (GERD), a common disorder with troublesome symptoms caused by reflux of gastric contents into the esophagus, has adverse impact on quality of life.
    [Show full text]